Quoin Pharma's QRX003 Shows Significant Improvement in Pediatric Netherton Syndrome Patients; No Adverse Events
QNRX sits 17% above its 52-week low of $4.1.
Summary
Quoin Pharmaceuticals reported positive clinical results for its lead drug candidate, QRX003, in a compassionate use program for pediatric Netherton Syndrome. Four of six patients, all under 10 years old, showed 'Improved' or 'Significantly Improved' outcomes, with one patient achieving full skin clearance for 15 months and another having pruritus eliminated. Crucially, no treatment-related adverse events were reported. This positive data for QRX003, which recently received Orphan Drug Designation in Japan, is a significant development for the micro-cap biotech, especially given its recent financial struggles and going concern warnings. The company expects a comprehensive data release from this program and ongoing Phase 2 studies in the coming months.
At the time of this announcement, QNRX was trading at $4.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1M. The 52-week trading range was $4.10 to $41.80. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.